• Dexamethasone (DHAP): Evidence and Scope

  2026-10-14

  APExBIO identifies Dexamethasone (DHAP), SKU A2324, as a synthetic glucocorticoid anti-inflammatory with reported activity across immune, stem-cell, cancer-cell, and neuroinflammation contexts. The product description supports a conceptual mechanism involving reduced activated NF-κB in immature dendritic cells, but it does not provide an identity-matched paper, sample sizes, effect estimates, or assay details. Accordingly, the reported readouts should be treated as product-description claims rather than independently verified evidence for this specific SKU.

• Editorial: What the LIRP Study Shows

  2026-10-14

  The cited 2026 Trends in Biotechnology study presents a light-inducible RNA-releasing protein (LIRP) as a conceptual gene-regulation platform for reversible, light-dependent control of therapeutic protein expression. Its mouse disease-model results support proof of principle, but the work does not establish clinical efficacy, long-term safety, or any connection to FH1, hepatocyte maturation, or iPS-derived liver-cell applications.

• Estradiol Benzoate: Evidence and Boundaries

  2026-10-13

  Estradiol Benzoate is described by its supplier as a synthetic estradiol analog and estrogen receptor alpha agonist for estrogen receptor signaling research. The supplied SARS-CoV-2 NSP15 study provides computational evidence for thymopentin and oleuropein, not for Estradiol Benzoate, so it does not establish antiviral activity or a mechanistic connection between the compound and NSP15.

• TMJ Inflammation, Microglia, and Synaptic Pruning

  2026-10-13

  A source-grounded overview of a mouse study linking TMJ inflammation with hippocampal microglial activation, Nr4a1 loss, neuronal C3 deposition, excessive synaptic pruning, and depression-like behaviors. The article also separates those findings from supplier-described claims about Verbascoside as a PKC/NF-κB inhibitor, emphasizing that no connection between the compound and the cited TMJ study is documented.

• Nr4a1, C3 and TMJ-Linked Synaptic Pruning

  2026-10-12

  A mouse study links TMJ inflammation with hippocampal microglial activation, altered Nr4a1 expression, neuronal C3 deposition and depression-like behaviors, while leaving important questions about human relevance and molecular specificity.

• VX-702 and the Dynamics of p38α MAPK Inhibition

  2026-10-12

  This overview separates supplier-reported properties of VX-702 from evidence in a non-peer-reviewed structural study of p38α MAPK regulation. The available evidence supports a mechanistic concept in which some inhibitors may both block kinase activity and promote phosphatase access, but it does not establish that VX-702 has this dual action or that preclinical findings translate to human treatment.

• Standardized Whole-Blood Stimulation and Immunometabolism

  2026-10-10

  Zhao and colleagues present a standardized whole-blood stimulation framework for examining how metabolic modulation changes human immune responses, with cytokine production as a principal readout. The protocol is valuable for cohort-scale immunometabolism research, but its ex vivo design supports hypothesis generation rather than direct conclusions about clinical efficacy, tumor responses, or specific therapeutic combinations.

• Ferrostatin-1 in Ferroptosis Research: Evidence and Limits

  2026-10-09

  Ferrostatin-1 (Fer-1) is a useful pharmacological probe for studying ferroptosis, but its value depends on careful interpretation. This overview separates supplier claims from peer-reviewed findings, examines the FHOD1–HSPB1 glioma study, and defines key evidence and applicability limits.

• Thrombin B-Chain Fragment: Research Context

  2026-10-09

  Thrombin is a central coagulation cascade enzyme, but a short B-chain fragment should not automatically be interpreted as equivalent to the complete protease. This overview separates supplier-reported product identity from peer-reviewed evidence on fibrin-matrix angiogenesis, compares the strength of those evidence types, and outlines scientifically defensible applications and limitations.

• Okadaic Acid Product Overview

  2026-10-08

  APExBIO’s SKU A4540 is listed as okadaic acid, a marine-derived inhibitor of PP1 and PP2A for conceptual studies of phosphorylation-dependent signaling and apoptosis. No matched paper evidence was available, so performance and applicability remain unverified.

• TMAO, PERK, and NAFLD: What the Study Shows

  2026-10-08

  A 2024 Toxicology Letters study used zebrafish and liver-cell models to examine whether trimethylamine N-oxide can directly drive NAFLD-like pathology and whether PERK signaling is involved. The findings connect TMAO exposure with steatosis, inflammation, liver injury, and fibrosis, while also identifying PERK activation as a plausible mechanistic link that still requires causal validation.

• CK2 Phosphorylation Tunes Plant Ceramide Synthase

  2026-10-07

  Zhang et al. show that casein kinase 2 phosphorylates the Arabidopsis ceramide synthase LOH2, increasing catalytic activity while also promoting polyubiquitination and proteasomal turnover. The study presents phosphorylation as a balancing mechanism that links C16 ceramide production with salicylic acid accumulation, cell death, and plant immune responses.

• Verbascoside: PKC/NF-κB Evidence Map

  2026-10-06

  Verbascoside is a supplier-described PKC/NF-κB inhibitor with an assay-specific reported IC50 of approximately 4.8 μM in RANKL-treated osteoclast precursor models. The available evidence supports osteoclastogenesis research and pathway-focused hypothesis generation, but it does not establish efficacy in TMJ inflammation, hippocampal synaptic pruning, or depression-like behavior.

• Hypoxia, FGFR1, and EGFR-TKI Resistance in NSCLC

  2026-10-06

  Lu and colleagues show that hypoxia can promote resistance to osimertinib in EGFR-mutant lung cancer models through FGFR1 activation, MAPK signaling, EMT-associated changes, and reduced BIM induction. The study supports a mechanistic rationale for combining EGFR inhibition with FGFR1 or MEK pathway blockade, while its preclinical design limits direct clinical generalization.

• PDHA1 Succinylation in Cholangiocarcinoma

  2026-10-05

  A 2025 Nature Communications study links PDHA1 K83 succinylation to altered tumor metabolism, α-ketoglutarate accumulation, and impaired macrophage antigen presentation in cholangiocarcinoma. The findings define a tumor–immune mechanism that may contribute to chemotherapy resistance, while remaining preclinical and requiring clinical validation.

8443 records 2/563 page Previous Next 12345 下5页 Last page